March 6, 2008 – Marcadia Biotech, Inc., a privately held drug development company, announced a strategic collaboration with Merck & Co., Inc. to jointly discover, develop and commercialize novel biopharmaceutical therapies targeting the glucagon and related receptors for the treatment of diabetes and obesity.
“Merck is a world leader in the discovery of breakthrough medicines and has proven expertise in the development and commercialization of drugs that treat metabolic diseases,” said Fritz French, CEO of Marcadia. “We are excited about the opportunity to significantly leverage the research we have accomplished to date through this collaboration with Merck.”... [PDF] Marcadia Biotech's Press Release -
Blog Archive
-
▼
2008
(55)
-
▼
March
(13)
- Sanofi-aventis : NICE Recommends Acomplia to be in...
- deCODE Obesity Genetics study merck
- Arena Pharmaceuticals' Lorcaserin for Obesity
- VIVUS, Enrollment in EQUATE (OB-301) Trial completed
- Thiakis, Novel therapy for treatment of obesity en...
- Alizyme's cetilistat,Phase III development program...
- Merck, Innovative Research Method to Identify Chan...
- Marcadia Biotech and Merck, strategic collaboration
- Hollis-Eden Pharmaceuticals, Positive Preliminary ...
- Bar Harbor BioTechnology : New Line of StellARrays
- EnteroMedics, Expansion of EMPOWER Pivotal Study f...
- OREXIGEN Therapeutics, European Patent Office Allo...
- Athersys, Results for Phase 1 Safety Study of Its ...
-
▼
March
(13)